U.S. markets closed
  • S&P Futures

    4,307.00
    -0.75 (-0.02%)
     
  • Dow Futures

    34,116.00
    -2.00 (-0.01%)
     
  • Nasdaq Futures

    13,650.00
    -8.25 (-0.06%)
     
  • Russell 2000 Futures

    2,023.80
    +0.50 (+0.02%)
     
  • Crude Oil

    86.77
    +0.24 (+0.28%)
     
  • Gold

    1,788.90
    -0.80 (-0.04%)
     
  • Silver

    20.06
    -0.02 (-0.12%)
     
  • EUR/USD

    1.0173
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    2.8240
    +0.0330 (+1.18%)
     
  • Vix

    19.69
    -0.26 (-1.30%)
     
  • GBP/USD

    1.2104
    +0.0009 (+0.08%)
     
  • USD/JPY

    134.2970
    +0.0820 (+0.06%)
     
  • BTC-USD

    23,973.49
    -145.91 (-0.60%)
     
  • CMC Crypto 200

    570.89
    -1.02 (-0.18%)
     
  • FTSE 100

    7,536.06
    +26.91 (+0.36%)
     
  • Nikkei 225

    29,113.37
    +244.46 (+0.85%)
     

Tempest to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the following investor conferences in September:

  • H.C. Wainwright 23rd Annual Global Investment Conference available on-demand Monday, September 13, 2021 at 7:00 a.m. ET

  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday September 22, 2021 at 9:55 a.m. ET

To access the live or archived recording of the company presentations, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contact:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media Contact:

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com